small dose glp 1 A practical guide to introducing and titrating GLP-1 therapies Noom Microdose GLP-1rx — Low

Summary measures and synthesis of results The principal summary outcome was the relative risk (RR) of several GI adverse events in people with overweight or obesity receiving treatment with GLP-1 RA, including nausea, vomiting, diarrhea, constipation, abdominal distension, upper abdominal pain, abdominal pain, abdominal discomfort, gastroesophageal reflux disease, (GERD), eructation, flatulence, decreased appetite, cholelithiasis, gallstone-related, cholecystitis, acute cholecystitis, acute pancreatitis, viral gastroenteritis, hard feces, and infrequent bowel movements

Hence why recent moves to cut them out of the picture could majorly slash access

Muscle is metabolically expensive for the body to maintain

Recent studies have raised concerns about a potential link between Ozempic (semaglutide) and serious vision problems, particularly the rare condition known as non-arteritic anterior ischemic optic neuropathy (NAION)